The only thing shareholder should be focused on is the breakeven number at EOY which is why 2nd quarter 4c will be crucial. SP will not breakout until the company can prove to the market that it can stand on its own.
If anyone is going to the AGM and feels the same way about how vital the numbers will make or break us in 2018, can someone please ask the following questions.
1. Are we still on track to hit 4.4m in CC sale in q2?
2. Is Admedus still forecasting a breakeven in the q4 with a total revenue of $34m in 2018?
2a - Given the numbers provided in the most recent presentation and q1 4c below, Admedus will not breakeven on a total revenue of 34m and total expenses $48m, is there anything else in the forecast we should know about?
|
Column 1 |
Column 2 |
Column 3 |
Column 4 |
Column 5 |
Column 6 |
Column 7 |
Column 8 |
| 1 |
Admedus 2018 forecast $'000 |
4th Q 2017 (Actual) |
1st Q 2018 (Actual) |
2nd Q 2018 (Forecast) |
3rd Q 2018 (Forecast) |
4th Q 2018 (Forecast) |
2018 Total (Forecast) |
Comment |
| 2 |
Sales |
6,300 |
6,200 |
8,400 |
9,200 |
10,200 |
34,000 |
|
| 3 |
Adapt |
2,100 |
2,200 |
4,400 |
5,200 |
6,200 |
18,000 |
19 April presentation |
| 4 |
Infusion |
4,200 |
4,000 |
4,000 |
4,000 |
4,000 |
16,000 |
19 April presentation |
| 5 |
Other Income |
- |
- |
- |
- |
- |
- |
|
| 6 |
Total revenue |
6,300 |
6,200 |
8,400 |
9,200 |
10,200 |
34,000 |
|
| 7 |
|
|
|
|
|
|
|
|
| 8 |
Cash receipt from operation |
6,484 |
6,776 |
8,400 |
9,200 |
10,200 |
34,576 |
|
| 9 |
Cash receipt from Investment |
- |
- |
|
|
|
|
|
| 10 |
Cash receipt from Grant |
- |
- |
|
|
|
|
|
| 11 |
Total Cash Receipt |
6,484 |
6,776 |
8,400 |
9,200 |
10,200 |
34,576 |
|
| 12 |
|
|
|
|
|
|
|
|
| 13 |
Operating expenses |
9,872 |
11,565 |
11,691 |
11,700 |
11,700 |
46,656 |
|
| 14 |
Investing expenses |
420 |
485 |
500 |
500 |
500 |
1,985 |
|
| 15 |
Currency movement |
|
176 |
|
|
|
|
|
| 16 |
Total Cash Outgoing |
10,292 |
12,226 |
12,191 |
12,200 |
12,200 |
48,641 |
|
| 17 |
Total Cashflow |
- 3,808 |
- 5,450 |
- 3,791 |
- 3,000 |
- 2,000 |
- 14,065 |
|
| 18 |
|
|
|
|
|
|
|
|
| 19 |
Cash at bank* |
8,255 |
7,805 |
4,014 |
1,014 |
- 986 |
|
Profile is prior to CR |
| 20 |
Loan Drawn* |
|
5,000 |
10,000 |
10,000 |
10,000 |
|
Profile is prior to CR |
*numbers are prior to placement
2b - how is the most recent recuritments going to impact our expense forecast in 2018 given they should be additional cost to the $48m quoted above (given acceleration of products will not increase revenue in 2018)?
Very indicative numbers used in the table above, however this is my number 1 concern for 2018.
(20min delay)